Alivus Life Sciences Ltd vs Laurus Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Laurus Labs Ltd changed from 19.8 on March 2021 to 92.4 on March 2025 . This represents a CAGR of 36.08% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Laurus Labs Ltd changed from ₹ 19427 crore on March 2021 to ₹ 33099 crore on March 2025 . This represents a CAGR of 11.24% over 5 years The revenue of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Laurus Labs Ltd for the Mar '26 is ₹ 1823 crore as compare to the Dec '25 revenue of ₹ 1784 crore. This represent the growth of 2.2% The ebitda of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Laurus Labs Ltd for the Mar '26 is ₹ 523.91 crore as compare to the Dec '25 ebitda of ₹ 485.97 crore. This represent the growth of 7.81% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Laurus Labs Ltd changed from ₹ 12.21 crore to ₹ 281.91 crore over 8 quarters. This represents a CAGR of 380.50% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Laurus Labs Ltd changed from 11.22 % on March 2021 to 17.01 % on March 2025 . This represents a CAGR of 8.68% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

FAQs for the comparison of Alivus Life Sciences Ltd and Laurus Labs Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Laurus Labs Ltd?

Market cap of Alivus Life Sciences Ltd is 12,733 Cr while Market cap of Laurus Labs Ltd is 59,335 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Laurus Labs Ltd?

The stock performance of Alivus Life Sciences Ltd and Laurus Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Laurus Labs Ltd?

As of May 4, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1037.5. On the other hand, Laurus Labs Ltd stock price is INR ₹1099.1.

How do dividend payouts of Alivus Life Sciences Ltd and Laurus Labs Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Laurus Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.